Associations of treatment factors and outcomes for CR rate and progression-free and OS
| Treatment factors . | Outcomes . | |||||
|---|---|---|---|---|---|---|
| Univariate analysis . | Multivariate analysis* . | |||||
| OR (95% CI; P) . | HR (95% CI; P) . | OR (95% CI; P) . | HR (95% CI; P) . | |||
| CR . | PFS . | OS . | CR . | PFS . | OS . | |
| Rituximab | ||||||
| Yes = 542; no = 1004 | 2.49 (1.98-3.15; <.001) | 0.53 (0.44-0.63; <.001) | 0.43 (0.37-0.51; <.01) | 2.89 (1.64-5.08; <.001) | 0.50 (0.34-0.72; <.001) | 0.51 (0.38-0.71; <.0001) |
| Chemoregimen | ||||||
| CHOP (n = 632) | 1.0 (reference) | 1.0 (reference) | 1.0 (reference) | 1.0 (reference) | 1.0 (reference) | 1.0 (reference) |
| Infusional regimens | ||||||
| EPOCH; n = 166 | 1.73 (1.17-2.57; .006) | 0.57 (0.41-0.79; <.001) | 0.59 (0.44-0.76; <.001) | 0.97 (0.42-2.24; .95) | 1.11 (0.56-2.05; .75) | 0.67 (0.33-1.22; .22) |
| CDE; n = 191 | 0.54 (0.39-0.75; <.001) | 1.10 (0.85-1.40; .46) | 0.95 (0.76-1.18; .64) | 0.87 (0.54-1.40; .55) | 0.93 (0.67-1.27; .64) | 0.73 (0.55-0.96; .03) |
| Dose-intense regimens | ||||||
| Intensive (n = 155) | 1.57 (0.97-2.55; .07) | 0.89 (0.66-1.18; .42) | 0.76 (0.58-0.99; .043) | 1.65 (0.57-4.77; .36) | 0.32 (0.18-0.54; <.0001) | 0.54 (0.36-0.82; .004) |
| ACVBP; 158 | 1.34 (0.91-1.97; .13) | 1.07 (0.81-1.39; .64) | 1.01 (0.80-1.26; .94) | 1.70 (1.04-2.79; .036) | 0.72 (0.52-0.99; .049) | 0.88 (0.67-1.16; .38) |
| Less dose-intense regimens | ||||||
| Low-dose/modified CHOP; n = 165 | 0.34 (0.23-0.49; .001) | 2.60 (2.04-3.28; <.001) | 2.59 (2.08-3.20; <.001) | 0.33 (0.19-0.58; <.001) | 2.11 (1.53-2.89; <.0001) | 1.91 (1.44-2.52; <.0001) |
| VS; n = 41 | 0.02 (0.003-0.14; <.001) | 7.27 (4.84-10.56; <.001) | 5.13 (3.58-7.14; <.001) | 0.04 (0.01-0.33; .002) | 3.34 (2.06-5.23; <.0001) | 2.41 (1.58-3.60; <.0001) |
| Remick; n = 38 | 0.32 (0.16-0.64; .001) | NA | 2.48 (1.72-3.47; <.001) | 0.77 (0.21-2.90; .70) | NA | 0.86 (0.46-1.51; .62) |
| Concurrent cART | ||||||
| Yes = 779; no = 724 | 1.39 (1.12-1.73; .003) | 0.78 (0.59-0.92; .006) | 0.45 (0.29-0.76; .001) | 1.89 (1.21-2.93; .005) | 0.89 (0.66-1.21; .45) | 0.78 (0.60-1.02; .07) |
| Treatment factors . | Outcomes . | |||||
|---|---|---|---|---|---|---|
| Univariate analysis . | Multivariate analysis* . | |||||
| OR (95% CI; P) . | HR (95% CI; P) . | OR (95% CI; P) . | HR (95% CI; P) . | |||
| CR . | PFS . | OS . | CR . | PFS . | OS . | |
| Rituximab | ||||||
| Yes = 542; no = 1004 | 2.49 (1.98-3.15; <.001) | 0.53 (0.44-0.63; <.001) | 0.43 (0.37-0.51; <.01) | 2.89 (1.64-5.08; <.001) | 0.50 (0.34-0.72; <.001) | 0.51 (0.38-0.71; <.0001) |
| Chemoregimen | ||||||
| CHOP (n = 632) | 1.0 (reference) | 1.0 (reference) | 1.0 (reference) | 1.0 (reference) | 1.0 (reference) | 1.0 (reference) |
| Infusional regimens | ||||||
| EPOCH; n = 166 | 1.73 (1.17-2.57; .006) | 0.57 (0.41-0.79; <.001) | 0.59 (0.44-0.76; <.001) | 0.97 (0.42-2.24; .95) | 1.11 (0.56-2.05; .75) | 0.67 (0.33-1.22; .22) |
| CDE; n = 191 | 0.54 (0.39-0.75; <.001) | 1.10 (0.85-1.40; .46) | 0.95 (0.76-1.18; .64) | 0.87 (0.54-1.40; .55) | 0.93 (0.67-1.27; .64) | 0.73 (0.55-0.96; .03) |
| Dose-intense regimens | ||||||
| Intensive (n = 155) | 1.57 (0.97-2.55; .07) | 0.89 (0.66-1.18; .42) | 0.76 (0.58-0.99; .043) | 1.65 (0.57-4.77; .36) | 0.32 (0.18-0.54; <.0001) | 0.54 (0.36-0.82; .004) |
| ACVBP; 158 | 1.34 (0.91-1.97; .13) | 1.07 (0.81-1.39; .64) | 1.01 (0.80-1.26; .94) | 1.70 (1.04-2.79; .036) | 0.72 (0.52-0.99; .049) | 0.88 (0.67-1.16; .38) |
| Less dose-intense regimens | ||||||
| Low-dose/modified CHOP; n = 165 | 0.34 (0.23-0.49; .001) | 2.60 (2.04-3.28; <.001) | 2.59 (2.08-3.20; <.001) | 0.33 (0.19-0.58; <.001) | 2.11 (1.53-2.89; <.0001) | 1.91 (1.44-2.52; <.0001) |
| VS; n = 41 | 0.02 (0.003-0.14; <.001) | 7.27 (4.84-10.56; <.001) | 5.13 (3.58-7.14; <.001) | 0.04 (0.01-0.33; .002) | 3.34 (2.06-5.23; <.0001) | 2.41 (1.58-3.60; <.0001) |
| Remick; n = 38 | 0.32 (0.16-0.64; .001) | NA | 2.48 (1.72-3.47; <.001) | 0.77 (0.21-2.90; .70) | NA | 0.86 (0.46-1.51; .62) |
| Concurrent cART | ||||||
| Yes = 779; no = 724 | 1.39 (1.12-1.73; .003) | 0.78 (0.59-0.92; .006) | 0.45 (0.29-0.76; .001) | 1.89 (1.21-2.93; .005) | 0.89 (0.66-1.21; .45) | 0.78 (0.60-1.02; .07) |
NA, not available.
All estimates in the multivariate analysis were adjusted for rituximab use, treatment, concurrent use of cART, age, gender, histological subtype, age-adjusted international prognostic index, CD4 count at baseline, prior history of AIDS, and enrollment period.